PPARA and metabolic dysfunction-associated steatohepatitis: Pemafibrate (K-877), a selective PPARα modulator, was demonstrated to improve liver pathology in the NASH mice model, and decrease serum transaminase activities and lipid profiles in patients with dyslipidemia [106].